Dexcom’s Trading Volume Climbs to 405th in U.S. Markets Amid Pre-Planned Insider Sales Stock Ends 0.16% Lower

On August 18, 2025, Dexcom (DXCM) recorded a trading volume of $0.24 billion, marking a 31.35% increase compared to the previous day, ranking it 405th in volume among listed stocks. The stock closed with a 0.16% decline, reflecting mixed investor sentiment amid insider activity reported earlier in the week.

Two insider transactions under 10b5-1 trading plans were disclosed on August 15, 2025. Michael Jon Brown, Dexcom’s Executive Vice President and Chief Legal Officer, sold 500 shares at $80.29 per share, totaling $40,145. Following the sale, Brown retained 94,102 shares, including 86,490 unvested restricted stock units. The transaction was executed under a pre-arranged plan established on February 21, 2025. Separately, Mark G. Foletta, a director, sold 2,750 shares via a trust, with the sales spread across trades at prices ranging from $80.29 to $81.22. Both sales were structured to comply with Rule 10b5-1, which allows pre-scheduled transactions to mitigate insider trading risks.

While insider selling is often scrutinized, transactions under 10b5-1 plans are typically pre-planned and not indicative of immediate bearish sentiment. However, the timing of these sales may contribute to short-term volatility as investors assess the implications for Dexcom’s broader ownership structure and management confidence. The company’s unvested restricted stock units, which remain subject to future performance or time-based conditions, suggest ongoing alignment between executives and long-term shareholder interests.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The total profit grew steadily over the period, with a few fluctuations due to market dynamics. As of the latest data, the strategy's total profit stands at $10,720.